欧盟药物专家组建议使用Dupixent治疗抗组胺药不反应的严重疹的儿童. EU drug panel recommends Dupixent for kids 2–11 with severe hives unresponsive to antihistamines.

欧洲药物管理局的CHMP建议扩大Dupixent的批准范围,以治疗中度至重度慢性自发性疹的2至11岁儿童,这些儿童未对抗组胺剂有反应,也未接受抗IgE治疗. The European Medicines Agency’s CHMP has recommended expanding Dupixent’s approval to treat children aged 2 to 11 with moderate-to-severe chronic spontaneous urticaria who haven’t responded to antihistamines and haven’t received anti-IgE therapy. 该建议是在欧盟2025年批准12岁以上病人之后提出的。 The recommendation follows its 2025 EU approval for patients 12 and older. 预计欧洲委员会不久将作出最后决定。 The European Commission is expected to make a final decision soon. 杜皮森特是一种针对免疫路径的生物药物,在2025年全球销售额达185亿美元. Dupixent, a biologic targeting immune pathways, generated $18.5 billion in global sales in 2025.